Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratz, Keith W., Panayiotidis, Panayiotis, Recher, Christian, Wei, Xudong, Jonas, Brian A., Montesinos, Pau, Ivanov, Vladimir, Schuh, Andre C., DiNardo, Courtney D., Novak, Jan, Pejsa, Vlatko, Stevens, Don, Yeh, Su-Peng, Kim, Inho, Turgut, Mehmet, Fracchiolla, Nicola, Yamamoto, Kazuhito, Ofran, Yishai, Wei, Andrew H., Bui, Cat N., Benjamin, Katy, Kamalakar, Rajesh, Potluri, Jalaja, Mendes, Wellington, Devine, Jacob, Fiedler, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021259/
https://www.ncbi.nlm.nih.gov/pubmed/35443742
http://dx.doi.org/10.1038/s41408-022-00668-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021259/
https://www.ncbi.nlm.nih.gov/pubmed/35443742
http://dx.doi.org/10.1038/s41408-022-00668-8

Ejemplares similares